Show simple item record

dc.contributor.authorO’Neill, Fiona
dc.contributor.authorMadden, Stephen F
dc.contributor.authorAherne, Sinead T
dc.contributor.authorClynes, Martin
dc.contributor.authorCrown, John
dc.contributor.authorDoolan, Padraig
dc.contributor.authorO’Connor, Robert
dc.date.accessioned2012-09-13T08:42:21Z
dc.date.available2012-09-13T08:42:21Z
dc.date.issued2012-06-18
dc.identifier.citationMolecular Cancer. 2012 Jun 18;11(1):41
dc.identifier.urihttp://dx.doi.org/10.1186/1476-4598-11-41
dc.identifier.urihttp://hdl.handle.net/10147/243756
dc.description.abstractAbstractBackgroundLapatinib, a tyrosine kinase inhibitor of HER2 and EGFR and is approved, in combination with capecitabine, for the treatment of trastuzumab-refractory metastatic breast cancer. In order to establish a possible gene expression response to lapatinib, a panel of breast cancer cell lines with varying sensitivity to lapatinib were analysed using a combination of microarray and qPCR profiling.MethodsCo-inertia analysis (CIA), a data integration technique, was used to identify transcription factors associated with the lapatinib response on a previously published dataset of 96 microarrays. RNA was extracted from BT474, SKBR3, EFM192A, HCC1954, MDAMB453 and MDAMB231 breast cancer cell lines displaying a range of lapatinib sensitivities and HER2 expression treated with 1 μM of lapatinib for 12 hours and quantified using Taqman RT-PCR. A fold change ≥ ± 2 was considered significant.ResultsA list of 421 differentially-expressed genes and 8 transcription factors (TFs) whose potential regulatory impact was inferred in silico, were identified as associated with lapatinib response. From this group, a panel of 27 genes (including the 8 TFs) were selected for qPCR validation. 5 genes were determined to be significantly differentially expressed following the 12 hr treatment of 1 μM lapatinib across all six cell lines. Furthermore, the expression of 4 of these genes (RB1CC1, FOXO3A, NR3C1 and ERBB3) was directly correlated with the degree of sensitivity of the cell line to lapatinib and their expression was observed to “switch” from up-regulated to down-regulated when the cell lines were arranged in a lapatinib-sensitive to insensitive order. These included the novel lapatinib response-associated genes RB1CC1 and NR3C1. Additionally, Cyclin D1 (CCND1), a common regulator of the other four proteins, was also demonstrated to observe a proportional response to lapatinib exposure.ConclusionsA panel of 5 genes were determined to be differentially expressed in response to lapatinib at the 12 hour time point examined. The expression of these 5 genes correlated directly with lapatinib sensitivity. We propose that the gene expression profile may represent both an early measure of the likelihood of sensitivity and the level of response to lapatinib and may therefore have application in early response detection.
dc.titleGene expression changes as markers of early lapatinib response in a panel of breast cancer cell lines
dc.typeJournal Article
dc.language.rfc3066en
dc.rights.holderFiona O’Neill et al.; licensee BioMed Central Ltd.
dc.description.statusPeer Reviewed
dc.date.updated2012-09-11T19:07:26Z
refterms.dateFOA2018-08-22T21:52:25Z
html.description.abstractAbstractBackgroundLapatinib, a tyrosine kinase inhibitor of HER2 and EGFR and is approved, in combination with capecitabine, for the treatment of trastuzumab-refractory metastatic breast cancer. In order to establish a possible gene expression response to lapatinib, a panel of breast cancer cell lines with varying sensitivity to lapatinib were analysed using a combination of microarray and qPCR profiling.MethodsCo-inertia analysis (CIA), a data integration technique, was used to identify transcription factors associated with the lapatinib response on a previously published dataset of 96 microarrays. RNA was extracted from BT474, SKBR3, EFM192A, HCC1954, MDAMB453 and MDAMB231 breast cancer cell lines displaying a range of lapatinib sensitivities and HER2 expression treated with 1 μM of lapatinib for 12 hours and quantified using Taqman RT-PCR. A fold change ≥ ± 2 was considered significant.ResultsA list of 421 differentially-expressed genes and 8 transcription factors (TFs) whose potential regulatory impact was inferred in silico, were identified as associated with lapatinib response. From this group, a panel of 27 genes (including the 8 TFs) were selected for qPCR validation. 5 genes were determined to be significantly differentially expressed following the 12 hr treatment of 1 μM lapatinib across all six cell lines. Furthermore, the expression of 4 of these genes (RB1CC1, FOXO3A, NR3C1 and ERBB3) was directly correlated with the degree of sensitivity of the cell line to lapatinib and their expression was observed to “switch” from up-regulated to down-regulated when the cell lines were arranged in a lapatinib-sensitive to insensitive order. These included the novel lapatinib response-associated genes RB1CC1 and NR3C1. Additionally, Cyclin D1 (CCND1), a common regulator of the other four proteins, was also demonstrated to observe a proportional response to lapatinib exposure.ConclusionsA panel of 5 genes were determined to be differentially expressed in response to lapatinib at the 12 hour time point examined. The expression of these 5 genes correlated directly with lapatinib sensitivity. We propose that the gene expression profile may represent both an early measure of the likelihood of sensitivity and the level of response to lapatinib and may therefore have application in early response detection.


Files in this item

Thumbnail
Name:
1476-4598-11-41.xml
Size:
106.4Kb
Format:
XML
Thumbnail
Name:
1476-4598-11-41.pdf
Size:
927.2Kb
Format:
PDF
Thumbnail
Name:
1476-4598-11-41-S2.XLS
Size:
35Kb
Format:
Microsoft Excel
Thumbnail
Name:
1476-4598-11-41-S5.XLS
Size:
27.5Kb
Format:
Microsoft Excel
Thumbnail
Name:
1476-4598-11-41-S4.XLS
Size:
22.5Kb
Format:
Microsoft Excel
Thumbnail
Name:
1476-4598-11-41-S6.PPT
Size:
625Kb
Format:
Microsoft PowerPoint
Thumbnail
Name:
1476-4598-11-41-S1.XLS
Size:
84Kb
Format:
Microsoft Excel
Thumbnail
Name:
1476-4598-11-41-S3.XLS
Size:
360Kb
Format:
Microsoft Excel

This item appears in the following Collection(s)

Show simple item record